ANI Pharmaceuticals (Nasdaq:ANIP) - Hisse Senedi Fiyatı, Haberler ve Analizler

ANIP Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan ANI Pharmaceuticals, Inc. Amerika Birleşik Devletleri ve Kanada'da markalı ve jenerik reçeteli ilaçlar geliştirmekte, üretmekte ve pazarlamaktadır.

Şirket hakkında

ANIP temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	2/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 78.8% daha düşük bir oranda işlem görüyor

Kazançların yılda 38.32% oranında artması öngörülüyor

Bu yıl karlı hale geldi

Analistler hisse senedi fiyatının 33.6% oranında artacağı konusunda hemfikir

Risk Analizi

Finansal sonuçları etkileyen büyük tek seferlik kalemler

Hissedarlar geçen yıl sulandırıldı

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector

Key Takeaways Accelerating demand for their lead Rare Disease asset and growth in generics, along with expanding sales efforts, are expected to significantly boost revenues. The acquisition of Alimera Sciences and significant manufacturing capacity expansion aim to enhance earnings and strengthen future growth in ophthalmology and generics.

View narrative

US$78.00

25.1% undervalued

11.92%

Revenue growth p.a.

Updated

ANI Pharmaceuticals, Inc. Rakipler

Collegium Pharmaceutical

NasdaqGS:COLL

US$1.1b

Harmony Biosciences Holdings

NasdaqGM:HRMY

US$1.9b

Elite Pharmaceuticals

OTCPK:ELTP

US$544.6m

Pacira BioSciences

NasdaqGS:PCRX

US$797.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti ANI Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$58.40
52 Haftanın En Yüksek Seviyesi	US$70.81
52 Haftanın En Düşük Seviyesi	US$48.20
Beta	0.71
11 Aylık Değişim	4.58%
3 Aylık Değişim	3.49%
1 Yıllık Değişim	7.51%
33 Yıllık Değişim	27.26%
5 Yıllık Değişim	2.96%
Halka arzdan bu yana değişim	826.98%

Son Haberler & Güncellemeler

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

Nov 02

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

Oct 11

Recent updates

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Sep 22

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Feb 22

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

Oct 28

ANI Pharma launches generic Prochlorperazine maleate tablets

Aug 29

ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval

Aug 16

ANI Pharmaceuticals Q2 2022 Earnings Preview

Aug 05

Hissedar Getirileri

	ANIP	US Pharmaceuticals	US Pazar
7D	-0.2%	-4.5%	2.3%
1Y	7.5%	10.9%	35.1%

Getiri vs. Endüstri: ANIP geçen yıl % 10.9 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: ANIP geçen yıl % 35.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ANIP's price volatile compared to industry and market?
ANIP volatility
ANIP Average Weekly Movement	5.8%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: ANIP son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ANIP 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2001	642	Nikhil Lalwani	www.anipharmaceuticals.com

Bir biyofarmasötik şirketi olan ANI Pharmaceuticals, Inc. Amerika Birleşik Devletleri ve Kanada'da markalı ve jenerik reçeteli ilaçlar geliştirmekte, üretmekte ve pazarlamaktadır. Şirket, oral katı doz ürünler; yarı katı, sıvı ve topikal ürünler; kontrollü maddeler ve potent ürünler üretmekte ve ayrıca farmasötik ürünlerin sözleşmeli geliştirme ve üretimini gerçekleştirmektedir. Ürünlerini perakende eczane zincirleri, toptancılar, distribütörler ve posta siparişi eczaneleri, grup satın alma organizasyonları, özel eczaneler ve hastaneler aracılığıyla pazarlamaktadır.

ANI Pharmaceuticals, Inc. Temel Bilgiler Özeti

ANI Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ANIP temel i̇stati̇sti̇kler
Piyasa değeri	US$1.12b
Kazançlar(TTM)	US$22.93m
Gelir(TTM)	US$538.95m

49.7x

F/K Oranı

2.1x

P/S Oranı

ANIP aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ANIP gelir tablosu (TTM)
Gelir	US$538.95m
Gelir Maliyeti	US$208.38m
Brüt Kâr	US$330.58m
Diğer Giderler	US$307.65m
Kazançlar	US$22.93m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 08, 2024

Hisse başına kazanç (EPS)	1.17
Brüt Marj	61.34%
Net Kâr Marjı	4.25%
Borç/Özkaynak Oranı	59.4%

ANIP uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ANIP Stoklara Genel Bakış

Ödüller

Risk Analizi

Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector

ANI Pharmaceuticals, Inc. Rakipler

NasdaqGS:COLL

US$1.1b

NasdaqGM:HRMY

US$1.9b

OTCPK:ELTP

US$544.6m

NasdaqGS:PCRX

US$797.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Recent updates

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of R&D notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Head of Rare Disease recently sold US$157k worth of stock

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

Head of R&D notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023